Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
96% of the 484 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.84 vs. PETS: No Debt )
PETS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.92
PETS's Equity to Asset is ranked higher than
99% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. PETS: 0.92 )
PETS' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.95
Current: 0.92

-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
98% of the 357 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.60 vs. PETS: No Debt )
PETS' s 10-Year Interest Coverage Range
Min: 15.27   Max: 9999.99
Current: No Debt

15.27
9999.99
F-Score: 5
Z-Score: 31.83
M-Score: 0.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.85
PETS's Operating margin (%) is ranked higher than
96% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. PETS: 11.85 )
PETS' s 10-Year Operating margin (%) Range
Min: -26.37   Max: 17.02
Current: 11.85

-26.37
17.02
Net-margin (%) 7.53
PETS's Net-margin (%) is ranked higher than
95% of the 479 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.36 vs. PETS: 7.53 )
PETS' s 10-Year Net-margin (%) Range
Min: -28.25   Max: 10.91
Current: 7.53

-28.25
10.91
ROE (%) 26.81
PETS's ROE (%) is ranked higher than
96% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.86 vs. PETS: 26.81 )
PETS' s 10-Year ROE (%) Range
Min: -372.96   Max: 58.25
Current: 26.81

-372.96
58.25
ROA (%) 23.46
PETS's ROA (%) is ranked higher than
99% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.39 vs. PETS: 23.46 )
PETS' s 10-Year ROA (%) Range
Min: -62.75   Max: 36.1
Current: 23.46

-62.75
36.1
ROC (Joel Greenblatt) (%) 91.00
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 478 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.26 vs. PETS: 91.00 )
PETS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -82.83   Max: 178.79
Current: 91

-82.83
178.79
Revenue Growth (%) 2.70
PETS's Revenue Growth (%) is ranked higher than
69% of the 329 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.40 vs. PETS: 2.70 )
PETS' s 10-Year Revenue Growth (%) Range
Min: 2.7   Max: 57.8
Current: 2.7

2.7
57.8
EBITDA Growth (%) -8.70
PETS's EBITDA Growth (%) is ranked higher than
61% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. PETS: -8.70 )
PETS' s 10-Year EBITDA Growth (%) Range
Min: -8.7   Max: 109.3
Current: -8.7

-8.7
109.3
EPS Growth (%) -9.00
PETS's EPS Growth (%) is ranked higher than
67% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.40 vs. PETS: -9.00 )
PETS' s 10-Year EPS Growth (%) Range
Min: -9   Max: 104.1
Current: -9

-9
104.1
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PETS Guru Trades in Q1 2013

Paul Tudor Jones 17,700 sh (New)
Steven Cohen 40,337 sh (New)
Joel Greenblatt 153,161 sh (+39.37%)
Jim Simons 1,211,200 sh (+1.24%)
Chuck Royce 56,000 sh (unchged)
John Buckingham 112,926 sh (-0.08%)
» More
Q2 2013

PETS Guru Trades in Q2 2013

John Hussman 15,000 sh (New)
Paul Tudor Jones 29,400 sh (+66.1%)
Jim Simons 1,354,115 sh (+11.8%)
John Buckingham 118,562 sh (+4.99%)
Chuck Royce 56,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 32,909 sh (-78.51%)
» More
Q3 2013

PETS Guru Trades in Q3 2013

Jim Simons 1,630,915 sh (+20.44%)
John Buckingham 119,189 sh (+0.53%)
Chuck Royce 56,000 sh (unchged)
John Hussman 15,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 19,800 sh (-32.65%)
» More
Q4 2013

PETS Guru Trades in Q4 2013

Chuck Royce 141,000 sh (+151.79%)
John Hussman 20,000 sh (+33.33%)
Jim Simons 1,893,015 sh (+16.07%)
John Buckingham 121,889 sh (+2.27%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PETS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Add 33.33%0.01%$14.58 - $16.86 $ 12.95-17%20000
Joel Greenblatt 2013-09-30 Sold Out 0.02%$12.82 - $17.17 $ 12.95-17%0
Joel Greenblatt 2013-06-30 Reduce -78.51%0.08%$12.37 - $13.73 $ 12.95-1%32909
John Hussman 2013-06-30 New Buy0.01%$12.37 - $13.73 $ 12.95-1%15000
Joel Greenblatt 2013-03-31 Add 39.37%0.03%$11.09 - $14.37 $ 12.951%153161
Joel Greenblatt 2012-06-30 Add 162.75%0.06%$11.15 - $13.46 $ 12.956%102679
Joel Greenblatt 2011-03-31 Add 326.98%0.2%$14.39 - $17.89 $ 12.95-15%53855
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.70
PETS's P/E(ttm) is ranked higher than
82% of the 432 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.70 vs. PETS: 14.70 )
PETS' s 10-Year P/E(ttm) Range
Min: 11.25   Max: 50.06
Current: 14.7

11.25
50.06
P/B 3.80
PETS's P/B is ranked lower than
56% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. PETS: 3.80 )
PETS' s 10-Year P/B Range
Min: 2.33   Max: 20.8
Current: 3.8

2.33
20.8
P/S 1.10
PETS's P/S is ranked lower than
63% of the 496 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. PETS: 1.10 )
PETS' s 10-Year P/S Range
Min: 0.84   Max: 3.51
Current: 1.1

0.84
3.51
PFCF 29.60
PETS's PFCF is ranked higher than
57% of the 294 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.92 vs. PETS: 29.60 )
PETS' s 10-Year PFCF Range
Min: 7.86   Max: 1221.5
Current: 29.6

7.86
1221.5
EV-to-EBIT 8.20
PETS's EV-to-EBIT is ranked higher than
88% of the 456 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. PETS: 8.20 )
PETS' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 42.1
Current: 8.2

4.7
42.1
PEG 6.80
PETS's PEG is ranked lower than
51% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.47 vs. PETS: 6.80 )
PETS' s 10-Year PEG Range
Min: 0.33   Max: 17.82
Current: 6.8

0.33
17.82
Shiller P/E 13.60
PETS's Shiller P/E is ranked higher than
90% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.16 vs. PETS: 13.60 )
PETS' s 10-Year Shiller P/E Range
Min: 9.84   Max: 124.94
Current: 13.6

9.84
124.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.90
PETS's Dividend Yield is ranked higher than
93% of the 410 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.85 vs. PETS: 4.90 )
PETS' s 10-Year Dividend Yield Range
Min: 0.51   Max: 5.85
Current: 4.9

0.51
5.85
Dividend Payout 0.71
PETS's Dividend Payout is ranked lower than
55% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. PETS: 0.71 )
PETS' s 10-Year Dividend Payout Range
Min: 0.31   Max: 0.81
Current: 0.71

0.31
0.81
Dividend growth (3y) 26.00
PETS's Dividend growth (3y) is ranked higher than
94% of the 232 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.80 vs. PETS: 26.00 )
PETS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 26

0
26
Yield on cost (5-Year) 4.90
PETS's Yield on cost (5-Year) is ranked higher than
83% of the 417 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.06 vs. PETS: 4.90 )
PETS' s 10-Year Yield on cost (5-Year) Range
Min: 0.51   Max: 5.85
Current: 4.9

0.51
5.85
Share Buyback Rate 4.10
PETS's Share Buyback Rate is ranked higher than
94% of the 270 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.10 vs. PETS: 4.10 )
PETS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -48.2
Current: 4.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.70
PETS's Price/Net Cash is ranked higher than
57% of the 23 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.00 vs. PETS: 7.70 )
PETS' s 10-Year Price/Net Cash Range
Min: 3.77   Max: 34.59
Current: 7.7

3.77
34.59
Price/Net Current Asset Value 5.60
PETS's Price/Net Current Asset Value is ranked higher than
72% of the 79 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.43 vs. PETS: 5.60 )
PETS' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 236
Current: 5.6

3.12
236
Price/Tangible Book 4.00
PETS's Price/Tangible Book is ranked lower than
57% of the 402 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. PETS: 4.00 )
PETS' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 36.5
Current: 4

1.56
36.5
Price/DCF (Projected) 1.10
PETS's Price/DCF (Projected) is ranked higher than
79% of the 235 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. PETS: 1.10 )
PETS' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 6.04
Current: 1.1

0.54
6.04
Price/Median PS Value 0.70
PETS's Price/Median PS Value is ranked higher than
94% of the 451 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. PETS: 0.70 )
PETS' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 1.88
Current: 0.7

0.14
1.88
Price/Graham Number 1.60
PETS's Price/Graham Number is ranked higher than
56% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. PETS: 1.60 )
PETS' s 10-Year Price/Graham Number Range
Min: 1.06   Max: 5.73
Current: 1.6

1.06
5.73
Earnings Yield (Greenblatt) 12.20
PETS's Earnings Yield (Greenblatt) is ranked higher than
89% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. PETS: 12.20 )
PETS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 21.2
Current: 12.2

2.4
21.2
Forward Rate of Return (Yacktman) 0.52
PETS's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.91 vs. PETS: 0.52 )
PETS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 64.7
Current: 0.52

0.1
64.7

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, GNC, APNHY, JCOUF, PMC » details
Traded in other countries:PQM.Germany
PetMed Express, Inc. was incorporated in the state of Florida in January 1996. The company is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. The Company offers consumers an alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. Its current product line contains approximately 3000 SKUS. These products include a majority of the well-known brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl. In March 2010, the Company started offering for sale additional pet supplies on its website, which are drop shipped to its customers with third parties. These pet supplies include: food, beds, crates, stairs, strollers, and other popular pet supplies. It attracted approximately 22.7 million visitors to its website during fiscal 2013. Its website allows customers to easily browse and purchase all of its products online. Its website is designed to be fast, secure, and easy to use with order and shipping confirmations, and with online order tracking capabilities. It provides its customers with toll-free telephone access to its customer care representatives. Its call center generally operates from 8:00 AM to 11:00 PM, Monday through Thursday, 8:00 AM to 9:00 PM on Friday, 9:00 AM to 6:00 PM on Saturday, and 10:00 AM to 5:00 PM on Sunday, Eastern Time. The process of customers purchasing products from 1-800-PetMeds consists of a few simple steps. A customer first places a call to its toll-free telephone number or visits its website. The following information is needed to process prescription orders: pet information, prescription information, and the veterinarian's name and phone number. This information is entered into its computer system. Then its pharmacists and pharmacy technicians verify all prescriptions. The order process system checks for the verification for prescription medication orders and a valid payment method for all orders. An invoice is generated and printed in its fulfillment center, where items are picked, and then shipped via United States Postal Service, Federal Express, or UPS. Its customers enjoy the convenience of rapid home delivery, with approximately 80% of all orders being shipped within 24 hours of ordering. Its operations are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide